March 4, 2024 7:46am
You will always need to cull the catch
Earnings: AxoGen (AXGN) on Tuesday
Pre-open Indications: 1 Sell into Strength, 4 Positive and 2 Negative Indications
Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!
Never leave an investor uninformed!
Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.
Monday: The pre-open Dow futures are DOWN -0.27% or (-105 points), the S&P futures are DOWN -0.11% or (-5 points) as the Nasdaq futures are UP +0.04% or (+7 points)
U.S. stock futures were mixed and falling slightly on Monday,
European markets traded lower,
Asia Pacific markets were mostly higher as Australia slipped.
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Friday, all indexes advanced Friday while the Nasdaq rose to an all-time high Friday, surpassing its 2021 record; as the Dow closed UP +90.99 points or +0.23%, the S&P closed UP +40.81 points +0.80% while the Nasdaq closed UP +183.02 points or +1.14%
Economic Data Docket: This week, investors will look for clues about the future direction of interest rates from Fed Chair Powell’s monetary policy updates to the House of Representatives on Wednesday and to the Senate on Thursday. <CNBC>
- The ADP Employment Survey and January job openings data will be released on Wednesday, providing further insight into the labor market.
- Manufacturing and nonfarm payrolls data for February will also be released on Friday.
Friday’s night RegMed Investors (RMi) Closing Bell: “another knee-jerk reaction but, to our advantage” … https://www.regmedinvestors.com/articles/13353
Q1/24: march – 1 positive close
- February – 1 market holiday, 11 positive and 9 negative closes
- January: 2 holidays, 11 negative and 8 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive indications:
Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
AxoGen (AXGN) closed up +$0.13 after Thursday’[s +$0.23 with a positive +$0.31 or +2.90% as earnings’ approach on 3/5, Tuesday.
Blueprint Medicine (BPMC) closed up +$1.60 after Thursday’s -$1.93, Wednesday’s -$4.34, Tuesday’s +$4.74 and last Monday’s +$5.56 with a positive+-$3.88 or +4.08% pre-open indication.
CRISPR Therapeutics (CRSP -$0.47 after Thursday’s -$3.46, Wednesday’s -$1.44, Tuesday’s +$3.06 and Monday’s +$2.07) with a positive +$0.75 or +0.90% pre-open indication.
Intellia Therapeutics (NTLA) closed up +$0.54 with a positive +$0.35 or +1.07% pre-open indication
Sell into Strength Indications:
Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Editas Medicine (EDIT) closed up +$0.47 after Thursday’s -$1.01, Wednesday’s +2.21$ and Tuesday’s +$0.80 with a positive +$0.24 or +2.28% pre-open indication
Negative Indications:
Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
BioLife Solutions (BLFS) closed up +$1.07 after Thursday’s -$0.20 after earnings release with a negative -$0.32 or -1.78% pre-open indication.
Voyager Therapeutics (VYGR) closed up +$1.12 with a negative -$0.29 or -3.07% pre-open indication
The BOTTOM LINE: Buy into some but, be ready to consolidate gains …
Over the past several weeks i.e., February, the sector has paused, run up, then paused or pulled back.
That start-stop action has created, I believe … some exit and a few buying opportunities, but not for long.
The cell and gene therapy sector equities popped on Friday after Thursday’s dive after Wednesday decent following Tuesday positive close following last Monday.
- The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.
19 (of 35 covered companies) have reported … RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/13166
I reiterate, “Don't chase the cell and gene therapy sector.”
Short and non-sweet: Buy into some oversold, with a few SELL into STRENGTH – accumulate some “powder” i.e., cash!
<span style="font-family:"rom Friday" s="" market:",serif'="">
From Friday’s market:
- the Nasdaq last week reached its seventh weekly gain in eight.
- After Nasdaq’s strong finish to the week, it’s now 5.8% above its 50-day moving average, slightly extended once again.
- The small-cap Russell 2000 jumped nearly 3%, just topping December's 22-month high.
- The 10-year Treasury yield tumbled 8 basis points to 4.18%, backing off 2024 highs.
However, with the strong finish to the week, the Nasdaq is now 5.8% above its 50-day moving average, slightly extended once again.
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
